NCT01103609View on ClinicalTrials.gov

Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Warfarin

Oral tablet od on Day 4

DRUG

Placebo

Oral tablet bd, stepwise increased

DRUG

AZD1656

Oral tablet bd, stepwise increased

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01103609 - Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients | Biotech Hunter | Biotech Hunter